Although renin and angiotensinogen are known to be subject to feedback regulation, the effects of angiotensin II (Ang II) on the regulation of angiotensin converting enzyme (ACE) 
T he synthesis of angiotensin II (Ang II) is principally regulated by the activity of two enzymes: renin and angiotensin converting enzyme (ACE). Although renin cleaves angiotensinogen to form the decapeptide angiotensin I, the final step of the renin-angiotensin cascade is catalyzed by the dipeptidyl carboxypeptidase ACE (kininase II, EC 3.4.15.1) to yield the biologically active octapeptide Ang 11.1 ACE gene expression and enzymatic activity are found in tissues of the cardiovascular and urogenital systems, with highest concentrations in the lung and testis. [2] [3] [4] [5] The regulation of the activity of other components of the renin-angiotensin system has been studied in considerable detail. Such studies have revealed that Ang II is one of the most potent factors in the regulation of renin and angiotensinogen synthesis.6-8 Ang II exerts a negative feedback on renin gene transcription and renal renin secretion.9-14 On the other hand, Ang II tubing was inserted in both femoral vein and artery. The venous line was filled with the respective infusate and attached to an Alzet osmotic minipump (Alza Corp., Palo Alto, Calif.) at a flow rate of 1.02 ml/hr. The arterial line was tunneled subcutaneously to the back of the neck for subsequent direct blood pressure measurement. Direct mean arterial blood pressure was measured in conscious animals on the third study day with a Statham Gould pressure transducer (Statham Instruments, Puerto Rico) connected to a polygraph (Grass Instrument Co., Quincy, Mass.). Rats were then decapitated. Blood and tissues were rapidly collected, frozen in liquid nitrogen, and stored at -75°C for subsequent analyses.
In the second protocol, animals were treated with quinapril (10 mg/kg per day in drinking water, n =8) or placebo (n=7) for 3 days. Animals were instrumented, and blood pressure was recorded on the third day in identical fashion.
In the third protocol, animals were treated with quinapril (10 mg/kg per day in drinking water, n=20) for 3 days. To further ensure acute ACE inhibition, each rat also received an additional dose of quinapril by gavage (10 mg/kg under light ether anesthesia) on the next morning (time 0). Animals were then studied 6, 24, 48, 96, and 168 hours after gavage (n=4 at each time point). A control group (n=8) was allowed free access to drinking water and received saline gavage at time 0. Control rats were studied at 6 and 168 hours after gavage (n=4 at each time point 
ACE mRNA Measurements
Homogenization of various tissues was carried out in 4 M guanidine thiocyanate, 0.5% sodium N-laurylsarcosine, 25 mM sodium citrate, 0.1 M mercaptoethanol, and 2 M CsCI; RNA was pelleted by ultracentrifugation. 25 The RNA was resuspended in 0.2 M sodium acetate, pH 5.5, rocked at 4°C for 1 hour, and precipitated in 2 vol ethanol. The precipitated RNA was dissolved in water, and the amount was quantitated by absorbance at 260 nm in duplicate. Comparisons of relative mRNA levels were made in reference to the same amount of total RNA applied per sample. Standard Northern blot analysis, using the formaldehydeagarose method,26 was carried out to exclude RNA degradation or unspecific cross hybridization of the probes ( Figure 1 ). In agreement with published data on human and murine testicular ACE mRNA, a shorter ACE transcript was obtained from rat testicular RNA ( Figure 1 ).327 For quantitation of ACE mRNA levels, slot-blot hybridization analyses were performed. Sam Autoradiograms generated by slot blots were scanned with a microdensitometer (LKB, Paramus, N.J.) with the background set to zero for each autoradiograph.
Regression lines were calculated from the integral values obtained by scanning the serial concentrations of each sample. The relative signals of the specific mRNA were estimated from the slope of the regression line, and only values of r>0.90 were accepted. The blots were washed and rehybridized with 3-actin cDNA. The signal for ACE mRNA was divided by the signal for the f3-actin mRNA for each sample, and results were expressed as ACE/13-actin mRNA ratios. Our intrablot and interblot coefficient of variations were 8% and 9%, respectively.
Statistical Analysis
All data are presented as mean-'-SEM. Average slopes of slot-blot autoradiographs were directly compared by Student's unpaired t tests. A two-way analysis of variance and Fisher's exact test for posthoc analyses were used for multiple comparisons in case of three or more comparisons between groups. The relations between Ang II plasma levels or blood pressures and pulmonary ACE mRNA levels were determined by rank correlation analysis (Spearman's p). Significance was accepted at p<0.05.
Results
In this investigation, we examined the feedback regulation of ACE expression by Ang II, the effector peptide of the renin-angiotensin system. ACE activity was measured in serum, lung, and testis, and ACE mRNA levels were examined in lung and testis, the tissues with the highest ACE levels.
Protocol 1: Effect of Exogenous Ang II Infusion
Ang II (100, 300, or 1,000 ng/kg per minute) infused intravenously by osmotic minipumps over 3 days increased plasma Ang II concentrations in a dose-dependent manner (Table 1) . Mean arterial blood pressure increased as well but was more variable with the highest dose of Ang II ( Table 1 ). The infusion of Ang II decreased ACE activity in the lung, as compared with the vehicle-infused control value (Figure 2 ). In parallel, pulmonary ACE mRNA levels decreased significantly in animals receiving the Ang II infusion (Figure 2 ). In contrast, the etfects of Ang II infusion on serum and testicular ACE activities were less pronounced. Testicular ACE activity tended to decline; however, a significant reduction was observed only with the lowest dose ( Figure 3 ). In contrast, testicular ACE mRNA levels were significantly decreased by Ang II infusion ( Figure  3 ). Serum ACE activity displayed no significant difference after 3 days of Ang II infusion with the low or medium dose (control, 54.3+5.8 nM/ml per minute; low dose, 50 .2±2.8 nM/ml per minute; medium dose, 48.3 ±4.7 nM/ml per minute). However, the high dose of Ang II infusion resulted in a 30% decrease in serum ACE activity (38.2-+ 3.3 nM/ml per minute, p<0.05).
Protocol 2: Effect ofACE Inhibition
In this protocol, ACE activity and ACE mRNA levels were studied after 3 days of ACE inhibition with quinapril (10 mg/kg per day) in drinking water. Blood pressure decreased significantly in quinapril-versus vehicle-treated animals ( (Figure 2 , p<0.001) ACE activities; in contrast, pulmonary ACE mRNA levels increased significantly as compared with levels in vehicle-treated control animals ( Figure 2 ). Interestingly, quinapril treatment did not change either testicular ACE activity or mRNA levels ( Figure 3 ).
Combined data from both protocols showed a significant negative correlation between pulmonary ACE mRNA levels and plasma Ang II levels (r= -0.554, p<0.005) and mean arterial blood pressure (r= -0.442, p<0.05) (Figure 4) . Furthermore, animals receiving Ang II infusion displayed a negative correlation between pulmonary ACE activity and plasma Ang II levels (r=-0.428, p=0.01) and mean arterial pressure (r=-0.390, p<0.05).
Protocol 3: Effect of Quinapril Withdrawal on Serum

ACE Activity
This protocol was designed to study whether the induction of tissue ACE during ACE inhibition will eventually lead to an increase in serum ACE activity after withdrawal of the ACE inhibitor. Animals were treated with 10 mg/kg per day quinapril in drinking water for 3 days, followed by a final dose (10 mg/kg) given by gavage (time 0). As compared with salinegavaged control animals, quinapril-treated animals displayed a marked decrease of serum ACE activity 6 hours after gavage. However, 48 
Discussion
Despite the wide clinical use of agents that interfere with the renin-angiotensin system, no previous reports appear to examine the direct effects of Ang II on the regulation of ACE activity. In the present investigation, Ang II infusion was related to decreased tissue ACE activity in the lung, suggesting negative feedback regulation of pulmonary ACE activity. Serum ACE activity decreased to a lesser extent after 3 days of Ang II infusion. However, the estimated half-life of circulating ACE in rats is 72 hours29'30 and may mask a more pronounced change.
Indirect evidence for a role of Ang II in the regulation of ACE activity was provided previously by investigations using ACE inhibitors. However, such studies were complicated by interference of the inhibitors with the measurement of ACE activity. Fyhrquist et al30,31 removed captopril and enalapril from patient serum or cell media by prolonged storage, chloramine treatment (captopril), or dialysis (enalapril) before measuring ACE activity and observed ACE induction during ACE inhibitor treatment. Jackson and Johnston32 studied the relation of plasma enalaprilat levels to plasma ACE The recent sequencing of the ACE gene3'42 and availability of cDNA probes now provides a highly specific method to study ACE synthesis and regulation. ACE gene expression has been demonstrated in numerous tissues, confirming that tissue ACE activities reflect local ACE synthesis rather than contamination of circulating ACE. 354344 In the present investigation, we used these molecular biological methods to study the feedback regulation of ACE by Ang II. Ang II infusion decreased ACE mRNA levels in the lung. The negative feedback regulation of ACE synthesis was confirmed by decreased pulmonary ACE activity. Interestingly, the decrease of tissue ACE mRNA levels was more pronounced than the decrease of tissue ACE activity. Our study does not address the possible mechanisms for this observation; however, the different half-lives of mRNA 48 Therefore, alternatively, the mechanism for Ang II effects on pulmonary and testicular ACE activity might be indirect.
To study the effects of blockade of Ang II production, rats were treated with the ACE inhibitor quinapril. Significant ACE inhibition in the lung was accompanied by an induction of pulmonary ACE mRNA. The induction of pulmonary ACE mRNA after 3 days of ACE inhibition was followed by a marked overshoot of serum ACE activity 48 and 96 hours after withdrawal of quinapril, providing more evidence for a negative feedback regulation of ACE by Ang II. According to the plasma half-life of quinapril (0.8 hours) and its active metabolite quinaprilat (1.9 hours), more than 99.9% of the last dose should have been excreted by the 48-hour time point.49 Therefore, discontinuation of treatment with the ACE inhibitor may unmask the induction of serum ACE during quinapril administration.
Ang II infusion did not result in a dose-dependent decrease in testicular ACE activity, despite a significant decrease in ACE mRNA levels. Furthermore, systemic ACE inhibition did not affect testicular ACE activity. Similar data have been reported by Jackson et al,5°who studied animals treated with perindopril. This finding is presumed to be due to a blood-testis barrier, which prevents ACE inhibition in this tissue. Interestingly, the induction of ACE mRNA levels in the quinapril-treated animals was observed only in lung, but not in testis. These findings suggest that factors other than circulating Ang II may be important for regulation of testicular ACE activity during Ang II infusion or ACE inhibition.
It cannot be determined from this study whether the induction of lung and plasma ACE can influence the long-term blood pressure and tissue functional responses to prolonged ACE inhibitor administration. Although no drug tolerance has been reported in hypertension, Packer et a15' have described that captopril failed to achieve a sustained hemodynamic response in approximately 25% of patients with heart failure. It is intriguing to speculate that a marked induction of ACE synthesis may overcome the tissue drug effect. Further studies on this possibility are clearly of interest.
In summary, Ang II regulates pulmonary ACE mRNA expression via a negative-feedback mechanism. ACE inhibition causes induction of pulmonary ACE mRNA, as well as an increase of serum ACE content, without an immediate effect on arterial blood pressure. These findings may provide an improved understanding of the feedback regulation of the renin-angiotensin system and novel insights into the action of ACE inhibitors on tissue ACE gene expression and activity.
